Nonclinical & Early Development Services
Optimize early drug development studies and decisions with our partner labs for First-in-Rodent®, in vitro ADME assays, and Model Informed Drug Development. We partner with our clients to help with candidate selection, dose prediction PK/PD, and Pre-IND readiness and transitions to early clinical development.
Key Features:
First-in-Rodent® Studies
Accelerate early safety and exposure insights through non-GLP rodent models tailored for candidate selection.
In Vitro ADME Assays
Screen compounds efficiently for absorption, metabolism, and elimination to inform early-stage decision-making.
Model-Informed Drug Development (MIDD)
Utilize PK/PD modeling and simulation to predict human dosing and optimize study designs.
Candidate Selection Support
Leverage integrated data and expert consultation to identify and advance the most promising preclinical candidates.
Pre-IND Readiness
Ensure smooth regulatory transitions with strategic guidance, data package development, and early clinical planning.
Why Choose Synaptigen?
Commitment to Advocacy: We place patients at the center of all we do, ensuring their voices are heard and respected.
Expertise in Clinical Trials: Our deep understanding of regulatory and operational complexities ensures smooth, patient-focused execution.
Scalable Solutions: From small studies to large-scale trials, we customize our services to meet your specific needs.
Benefits for Patients and Sponsors:
For Patients: Improved trial experiences, accessible resources, and the assurance that their contributions will make a meaningful impact.
For Sponsors: Increased trial participation, better retention rates, and data integrity through enhanced patient engagement.
At SYNAPTIGEN, we’re not just running trials—we’re reshaping the way clinical research values and incorporates the human experience. Let us help you create trials that truly prioritize patients first.